Relation between score for allergic rhinitis and immunoglobulin-E levels in the local population

Authors

  • Saai Ram Thejas RVM Institute of Medical Sciences, Siddipet District, Telangana, India http://orcid.org/0000-0003-1854-3938
  • C. R. Vijay Bharath Reddy RVM Institute of Medical Sciences, Siddipet District, Telangana, India

DOI:

https://doi.org/10.18203/issn.2454-5929.ijohns20213277

Keywords:

Allergic rhinitis, Score for allergic rhinitis, Immunoglobulin E, Corticosteroids, Antihistamines

Abstract

Background: Allergic rhinitis (AR) is the most prevalent atopic disease in the world. It involves clinical hypersensitivity of the nasal mucosa to foreign substances mediated through immunoglobulin E antibodies. The quantitative Score for allergic rhinitis (SFAR) ranging between 0 and 16 has been in use from 2002.

Methods: 240 patients diagnosed with Persistent allergic rhinitis (PAR) were taken to be part of the study after proper consent irrespective of the severity of symptoms. Each patient filled out the SFAR form before the treatment commenced. Serum IgE levels were noted and treatment was started which included oral and topical antihistamines, oral leukotriene receptor antagonists along with intranasal steroids. The IgE values were assessed along with the SFAR values side by side to look for any association.  

Results: It was noted that the individuals with identified triggers of allergy and those with a positive family history of allergy had a considerable higher IgE value as compared to those who did not. The ones with a trigger identified as a cause had a 54.88% higher IgE value. The ones with positive family history had 47.12% higher IgE than the ones without a history of allergy.

Conclusions: Patients with well-defined trigger agents of allergy and positive family history of allergy are at a higher risk as they have a higher IgE value. They should be advised regular follow-ups and be monitored closely.

References

Meltzer EO, Nathan R, Derebery J, Stang PE, Campbell UB, Yeh WS, et al. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc. 2009;30(3):244-54.

Dykewicz MS, Fineman S. Executive Summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. Ann Allergy Asthma Immunol. 1998;81(5):463-8.

Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy. 2005;60(3):350-3.

Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(86):8-160.

Wittig HJ, Belloit J, Fillippi I, Royal G. Age-related serum immunoglobulin E levels in healthy subjects and in patients with allergic disease. J Allergy Clin Immunol. 1980;66(4):305-13.

Maesano I, Didier A, Klossek M, Chanal I, Moreau D, Bousquet J. The score for allergic rhinitis (SFAR): a simple and valid assessment method in population studies. Allergy. 2002;57(2):107-14.

Scadding GK. Corticosteroids in the treatment of pediatric allergic rhinitis. J Allergy Clin Immunol. 2001;108(1):59-64.

Walker SM, Durham SR, Till SJ, Roberts G, Corrigan CJ, Leech SC, Krishna MT, et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy. 2011;41(9):1177-200.

Johansson SG. Serum IgND levels in healthy children and adults. Int Arch Allergy Appl Immunol. 1968;34(1):1-8.

Kjellman NM, Johansson SG, Roth A. Serum IgE levels in healthy children quantified by a sandwich technique (PRIST). Clin Allergy. 1976;6(1):51-9.

Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950-8.

Baharudin A, Abdul LAH, Woo K, Yap FB, Tang IP, Leong KF, et al. Using Patient Profiles To Guide The Choice Of Antihistamines In The Primary Care Setting In Malaysia: Expert Consensus And Recommendations. Ther Clin Risk Manag. 2019;15:1267-75.

Storms WW. Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis. J Allergy Clin Immunol. 2004;114(5):146-53.

Krishnamoorthy M, Mohd NN, Mat LN, Abdullah B. Efficacy of Montelukast in Allergic Rhinitis Treatment: A Systematic Review and Meta-Analysis. Drugs. 2020;80(17):1831-51.

Cingi C, Songu M, Ural A, Maesano I, Erdogmus N, Bal C, Kahya V, et al. The Score For Allergic Rhinitis study in Turkey. Am J Rhinol Allergy. 2011;25(5):333-7.

Bernstein DI, Schwartz G, Bernstein JA. Allergic Rhinitis: Mechanisms and Treatment. Immunol Allergy Clin North Am. 2016;36(2):261-78.

Ologe FE, Adebola SO, Dunmade AD, Adeniji KA, Oyejola BA. Symptom score for allergic rhinitis. Otolaryngol Head Neck Surg. 2013;148(4):557-63.

Downloads

Published

2021-08-23

Issue

Section

Original Research Articles